Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126038962 | 12603896 | 2 | F | 201603 | 20160805 | 20160728 | 20160809 | EXP | TH-PFIZER INC-2016333230 | PFIZER | 67.00 | YR | F | Y | 0.00000 | 20160809 | CN | TH | TH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126038962 | 12603896 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | Oral | 50 MG (12.5 MGX4CAPSULES), DAILY | Y | 21938 | 50 | MG | CAPSULE, HARD | ||||||
| 126038962 | 12603896 | 2 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 12.5 MG, DAILY | Y | 21938 | 12.5 | MG | CAPSULE, HARD | ||||||
| 126038962 | 12603896 | 3 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 25 MG (12.5 MGX2 CAPSULES), DAILY | Y | 21938 | 25 | MG | CAPSULE, HARD | ||||||
| 126038962 | 12603896 | 4 | C | AMLODIPINE BESILATE | AMLODIPINE BESYLATE | 1 | UNK | 0 | |||||||||||
| 126038962 | 12603896 | 5 | C | PROPANOLOL /00030001/ | PROPRANOLOL HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126038962 | 12603896 | 6 | C | ASPIRIN /00002701/ | ASPIRIN | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126038962 | 12603896 | 1 | Metastatic renal cell carcinoma |
| 126038962 | 12603896 | 4 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126038962 | 12603896 | DE |
| 126038962 | 12603896 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126038962 | 12603896 | Disease progression | |
| 126038962 | 12603896 | Dysgeusia | |
| 126038962 | 12603896 | Lip dry | |
| 126038962 | 12603896 | Metastatic renal cell carcinoma | |
| 126038962 | 12603896 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126038962 | 12603896 | 1 | 201603 | 201603 | 0 | |
| 126038962 | 12603896 | 2 | 201604 | 0 | ||
| 126038962 | 12603896 | 3 | 2016 | 0 |